alovudine has been researched along with Carcinoma, Ductal, Breast in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fujiwara, Y; Hamada, A; Hashimoto, J; Kanayama, Y; Kodaira, M; Kurihara, H; Miyakita, Y; Shimizu, C; Tamura, K; Tani, H; Watanabe, Y; Yamamoto, H; Yonemori, K; Yoshida, M; Yunokawa, M | 1 |
Boin, C; Bousquet, G; Cuvier, C; EspiƩ, M; Giacchetti, S; Groheux, D; HindiƩ, E; Misset, JL; Moretti, JL; Teyton, P | 1 |
2 review(s) available for alovudine and Carcinoma, Ductal, Breast
Article | Year |
---|---|
Molecular imaging using PET for breast cancer.
Topics: Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Cetuximab; Dideoxynucleosides; ErbB Receptors; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Molecular Imaging; Norprogesterones; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Receptors, Vascular Endothelial Growth Factor; Trastuzumab | 2016 |
[PET/CT in breast cancer: an update].
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Dideoxynucleosides; Estradiol; Female; Fluorodeoxyglucose F18; Humans; Lymph Node Excision; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Sodium Fluoride; Treatment Outcome | 2009 |